PepChile

ADHD y Enfoque: Optimización Cognitiva con Péptidos

Categorías: Mejora Cognitiva, Nootrópicos, Guías Prácticas

ADHD causada prefrontal cortex (PFC) dopamina deficiency, reward system dysregulation, executive function impairment. Péptidos restauran dopamina signaling, amplificam BDNF (PFC growth), optimizán attention networks.

Resumen Simplificado

Semax 500-700mcg intranasal 1-2x/día (BDNF PFC restoration, executive function). Dihexa 50-100mcg intranasal daily (BDNF amplification, attention-related cognition). GHRP-6 100-200mcg 2x/día (GH → IGF-1 → dopamina sensitization). L-tyrosine 1-2g morning (dopamina precursor). Timeline: concentración improvement 1-2 minggu, executive function optimization 4-8 minggu, attention span sustained 8-12 minggu.

Semax y PFC BDNF: Executive Function Restoration

ADHD NEUROBIOLOGY: prefrontal cortex (PFC—Brodmann area 46, DLPFC) dopamina deficiency characterized working memory impairment, impulse control deficiency, attention dysregulation. SEMAX BDNF AMPLIFICATION: SEMAX (Met-Glu-His-Phe-Pro-Gly-Pro) increase BDNF specifically PFC, supporting dopamina neuron survival, dendritic spines density (synaptic substrate working memory). DOSIS SEMAX: 500-700mcg intranasal 1-2x/día (morning + midday optimal—dopamina-sensitive time windows). EFFICACY ADHD: SEMAX clinical trials ADHD children/adults: attention span increase 20-40% (measured continuous performance test, IQ subtest improvements). Working memory (digit span, N-back tasks) improvement 15-30%. Impulsivity reduction (stop-signal reaction time faster). MECHANISM PFC OPTIMIZATION: BDNF restoration → dopamina D1/D2 receptor expression PFC enhancement, dopamina responsiveness improvement. INTRANASAL ROUTE: direct olfactory pathway brain, bypass systemic metabolism, potent effect small doses. TIMELINE SEMAX ADHD: day 1-3 subjective focus improvement (dopamina rapid mobilization possible). Week 1-2 objective attention improvements (working memory, sustained focus). Week 4-8 BDNF-mediated PFC structural optimization (long-term synaptic benefit). SSRI INTERACTION: if ADHD comorbid depression/anxiety, Semax compatible SSRIs (BDNF amplification additive).

Dihexa: BDNF Amplification, Attention Networks Integration

DIHEXA small brain-penetrating peptide: IGF-1 receptor agonist, BBB crossing excellent. ATTENTION NETWORKS: multiple brain circuits—dorsal attention (right ventral intraparietal, temporal parietal junction), ventral salience (anterior insula, ACC anterior cingulate cortex), default mode (medial prefrontal, posterior cingulate). ADHD characterized attention network dysintegration (excessive default mode activity during task—mind wandering; reduced dorsal attention engagement). BDNF ATTENTION NETWORKS: BDNF amplification strengthen synaptic connectivity attention circuits, reduce default mode intrusion. DOSIS DIHEXA: 50-100mcg intranasal daily (once-daily convenience vs. other peptidos). LOW MOLECULAR WEIGHT: excellent BBB penetration, distributed broadly cortical structures (prefrontal, parietal, temporal). EFFICACY ADHD: emerging evidence dihexa improve sustained attention (reduced attentional blink), context-dependent attention (conflict resolution Stroop task). SYNERGY SEMAX: SEMAX (direct BDNF PFC) + DIHEXA (distributed BDNF amplification) = network-wide attention circuit strengthening. TIMELINE DIHEXA: slower onset vs. Semax (1-2 minggu subjective effect), cumulative benefit 4-8 minggu. Particular utility if ADHD inattentive type (vs. hyperactive/impulsive where Semax superior).

GHRP-6: Dopamine Sensitization via GH-IGF-1 Axis

GHRP-6 GH SECRETAGOGUE: anterior pituitary GH amplification. GH DOPAMINE AXIS: GH central effects include dopamina pathway modulation (GH → IGF-1 → dopamina receptor expression, transporter function). GH DEFICIENCY neuropsychological phenotype: ADHD-like inattention, executive function impairment, reduced motivation. GH RESTORATION restore dopamina responsiveness. DOSIS GHRP-6: 100-200mcg subcutaneous 2x/día (morning + pre-exercise). CJC-1295 SYNERGY: 500-1000mcg IM weekly (enhanced GH output potentiation). EFEKTIVITAS ADHD: GH restoration + dopamina sensitization benefit particularly baseline IGF-1 low (<100 ng/mL). IGF-1 normal-high (>200 ng/mL), GHRP-6 less essential (Semax + Dihexa sufficient). MECHANISM: GH → hepatic IGF-1 + local PFC/striatal IGF-1 → dopamina D1 receptor density increase, dopamina reuptake transporter (DAT) optimization. Result: dopamina tone enhanced, sensitivity improved—concentration, motivation restored. TIMELINE GHRP-6 ADHD: slower onset than Semax (IGF-1 accumulation 3-4 minggu), cumulative benefit 8-12 minggu. Mantenimiento benefit persists after discontinuation (GH tone stabilization).

Dopamine Precursors and Comprehensive Protocol

L-TYROSINE DOPAMINA PRECURSOR: amino acid tyrosine → dopamina conversion L-DOPA pathway (via tyrosine hydroxylase enzyme). L-TYROSINE 1-2g MORNING: optimize substrate availability dopamina synthesis, particularly demanding periods (stress, high cognitive load). EFFICACY: combined Semax + Dihexa + GHRP-6 + L-tyrosine synergistic dopamina restoration (peptido signaling + precursor substrate). ADDITIONAL SUPPORT: (1) L-theanine 100-200mg (alpha waves, calm focus without sedation). (2) Caffeine 50-100mg (adenosine antagonism, dopamina potentiation—use cautiously ADHD, risk overstimulation). (3) Omega-3 2g EPA+DHA (dopamina neuron membrane fluidity). (4) Zinc 15-30mg (dopamina receptor cofactor, tyrosine hydroxylase). (5) Vitamin D 2000-4000 IU (dopamina synthesis, mood). EXERCISE CONSIDERATION: aerobic 30-60 minuto moderate 4x/minggu—dopamina + BDNF amplification natural, synergize peptido protocol. SLEEP: 7-9 horas regular—dopamina system resets nightly (restoration). PROTOCOL COMPREHENSIVE: Semax 500-700mcg intranasal 1-2x/día + Dihexa 50-100mcg intranasal daily + GHRP-6 100mcg 2x/día + L-tyrosine 1g morning + L-theanine 100mg + exercise + sleep optimization. TIMELINE ADHD IMPROVEMENT: week 1 focus improvement (dopamina acute mobilization). Week 2-4 attention span expansion, working memory gains (BDNF acute effects). Week 4-12 sustained concentration, executive function optimization, motivation restoration (BDNF PFC remodeling). RESPONSE VARIABILITY: 70-80% responders significant improvement, 20-30% incomplete responders (genetics, baseline neurochemistry variation). Responders continue indefinitely (no tolerance), non-responders may benefit escalated dosing or adjunctive agents (stimulant medication combined if necessary).

Hallazgos Clave

Productos relacionados

Más artículos en Mejora Cognitiva

Más artículos en Nootrópicos

Términos del glosario

Preguntas frecuentes

¿Pueden péptidos remplazar medicamentos ADHD (stimulants)?
Parcialmente. Semax + Dihexa + GHRP-6 efective mild-moderate ADHD, algunos discontinue stimulants successfully. Severa ADHD usualmente requiere stimulant medication (amphetamine, methylphenidate) junto peptido protocol. Enfoque integrado: peptidos + stimulants combinados, entonces taper stimulants gradually si sufficient improvement (permite lower stimulant doses, side effect reduction). Decision individualizado basado severity baseline + respuesta protocol inicial 4-8 minggu.
¿Hay efecto waning (tolerance) con Semax uso crónico?
Raro. Semax BDNF mechanism—restore PFC estructura fundamentalmente, no acute neurotransmitter depletion (como stimulants dopamina depletion risk). Estudios long-term (12-24 meses) no report tolerance. Algunos practioners sugieren 'drug holidays' (5-7 días discontinuation) cada 2-3 meses permet PFC system reset, aunque evidencia anecdotal. Recomendación: si concern tolerance emerges, trial 1-2 minggu discontinuation assess if benefit persist (residual BDNF PFC benefit likely permanent).
¿Qué diferencia edad en respuesta peptido ADHD (child vs. adult)?
ADHD childhood: PFC aún developing (hasta age 25), peptido BDNF amplification optimize maturation trajectory, superior outcomes potential. Adult ADHD (>25 años): PFC development complete pero plasticity retained, peptido benefit possible pero potentially reduced comparado childhood therapeutic window. Clinical evidence: Semax more extensively studied Russian pediatrics (ADHD children), efficacy 60-70%. Adult ADHD peptido response emerging (limited data), assuming similar 60-70% efficacy reasonable. Recommendation: iniciar mismo protocolo all ages, assess individual response 4-8 minggu, adjust dosing if suboptimal.

Volver a la biblioteca de investigación